Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript

Group 1 - The company is experiencing significant growth in prescriptions since February, indicating a successful strategy despite not participating in TDAPA [2][3] - There is a month-over-month increase in total prescriptions, including patient assistance, commercial, and Medicaid [2] - Although growth is present, it is not at the desired pace [3]